BioNTech's Phase 2/3 trial for BNT113 plus pembrolizumab missed the PFS endpoint in HPV16+ head and neck cancer. The trial continues for the OS endpoint, which could still yield a positive outcome.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
